AGIO Insider Trading Activity and SEC Form 4 Filings
AGIO insider trading summary
Over the past 12 months, insiders at Agios Pharmaceuticals, Inc. (AGIO) reported 34 sales worth $3.7M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $3.7M.
Latest AGIO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 26, 2026 | Sarah Gheuens | Chief Medical Officer | Sell | $296K (7,866 @ $37.69) |
| Oct 22, 2026 | Sarah Gheuens | Chief Medical Officer | Sell | $19K (500 @ $37.52) |
| Oct 21, 2026 | Sarah Gheuens | Chief Medical Officer | Sell | $56K (1,489 @ $37.53) |
| Apr 2, 2026 | James William Burns | Chief Legal Officer | Sell | $114K (3,280 @ $34.71) |
| Apr 2, 2026 | Cecilia Jones | Chief Financial Officer | Sell | $109K (3,141 @ $34.71) |
| Apr 2, 2026 | Sarah Gheuens | Chief Medical Officer | Sell | $102K (2,940 @ $34.71) |
| Apr 2, 2026 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | Sell | $103K (2,959 @ $34.71) |
| Apr 2, 2026 | Tsveta Milanova | Chief Commercial Officer | Sell | $113K (3,262 @ $34.71) |
| Apr 2, 2026 | Brian Goff | Chief Executive Officer | Sell | $229K (6,596 @ $34.71) |
| Apr 2, 2026 | Brian Goff | Chief Executive Officer | Sell | $433K (12,472 @ $34.71) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.